Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases.
FAIL · Does not pass the screen
89.93 USD
Screen close, 2026-10-01 · not a live quote Last reviewed 4 days ago
Screened 2026-10-01 · the tape above runs as of 05:02 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 89.93 against the desk's fair-value range, base estimate 122.00, over the last year.
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price89.93 USD
Fair value122.00
Ethical score70.0/100
Our investment reviews on this name
2026-09-14Read Markdown90.60-0.7% to today ✓
2026-08-14Read Markup103.42-13.0% to today
2026-07-02Read Accumulation80.79+11.3% to today ✓
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Spyre Therapeutics, Inc. holds its Markdown at $89.93. Elevated stress, defensive posture warranted, held for 12 days.
As held on the ledger · 2026-10-01
Phase
Markdown · caution
Quantitative state
Elevated stress, defensive posture warranted, held for 12 days
Price at the screen
$89.93
Valuation
N/A trailing · -25.55 forward price to earnings
Values screen
FAIL· score 70.0
Beta
3.00
The Workings
Five Screens, Shown in Full
Does not pass. Interest-bearing securities
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
Excluded
Below 33%
Interest-bearing debt is of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
86.25%
Below 33%
Interest-bearing cash and securities are 86.2% of assets, above the one-third limit.
Fail
Receivables
11.02%
Below 49%
Money owed to the company is 11.0% of assets, under the 49% limit.
Pass
Revenue purity
Excluded
Below 5%
of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Spyre Therapeutics,'s business is fine, but its cash and interest-bearing securities are about 86% of its assets, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-10-04. It updates when the underlying figures move, and past reads are kept below.
Fair value range in USD, drawn from the 2026-10-01 screen. The gold marker is the market price at the same screen. A 35.7% margin of safety to the base estimate.
Third-party analyst targets: 14 covering, consensus Strong Buy. The average target sits +36% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-01 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
High priced hopes in an unproven biotech
Imagine handing cash to a lab that has never made a penny and shows no path to doing so. Spyre Therapeutics sits at that stage, a clinical developer with zero profit margins and a return on equity of minus 31 percent. The shares trade near our fair value yet carry an opportunity rating of none.
We pass. Forward earnings sit at a negative 32 times, the ethical screen returns insufficient data, and the business remains years from any commercial product. Analyst targets cluster around the current price, yet that consensus ignores the structural reality of pre revenue drug development.
Even a narrow margin of safety offers little comfort when success hinges on binary trial outcomes and dilution risk stays ever present. Clinical stage bets of this kind routinely destroy capital before any medicine reaches patients. Analysis, not advice.
The risks · The things to watch: it already moves more than the market on an average day; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
SYRE trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-02Markdown$89.93-0.7%Entry 6
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 99% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 305%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (15 analysts) rates it strong buy, with a mean price target of $95.
2026-09-14Markdown · changed$90.60-12.4%Entry 5
The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 12.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 99% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 305%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (15 analysts) rates it strong buy, with a mean price target of $95.
2026-08-14Markup · changed$103.42+28.0%Entry 4
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 28.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 99% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 305%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (15 analysts) rates it strong buy, with a mean price target of $95.
2026-07-18Accumulation$80.79+0.0%Entry 3
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 99% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 305%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (15 analysts) rates it strong buy, with a mean price target of $95.
2026-07-03Accumulation$80.79+0.0%Entry 2
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Accumulation$80.79Entry 1
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
